Substance / Medication

Mirabegron

Overview

Active Ingredient
mirabegron
RxNorm CUI
1300786
Labeler: Lupin Pharmaceuticals, Inc.Updated: 2025-12-24T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

29 trials linked to this intervention

29
Total Trials
8
Recruiting
14
With Results

Research Evidence

Published studies and systematic reviews

Sort:
An updated meta-analysis of head-to-head trials comparing the efficacy, safety, and adherence of mirabegron and vibegron in overactive bladder.
Bai Wei-Zhen, Zhou Shi-Yu, Mou Yuan-Yuan et al. · Medicine (Baltimore) · 2025
PMID: 41366890Meta-AnalysisFull text (PMC)
Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome-A Systematic Review.
Dey Anirban, Georgiadis Georgios, Umezurike Justin et al. · Eur Urol Focus · 2025
PMID: 39343691Meta-Analysis
Mirabegron Add-On Tamsulosin for Men with Overactive Bladder Symptoms: A Pooled Analysis of Four Randomized Controlled Trials.
Wu Yonglu, Li Guanjun, Zhou Haimin et al. · Urol Int · 2024
PMID: 38185112Meta-Analysis
Effects of mirabegron on brown adipose tissue and metabolism in humans: A systematic review and meta-analysis.
Ma Lili, Xiong Lianqiu, Huang Gang · Eur J Clin Pharmacol · 2024
PMID: 38159219Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mirabegron (substance)
SNOMED CT
703803006
UMLS CUI
C2983812
RxNorm CUI
1300786
Labeler
Lupin Pharmaceuticals, Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
29
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.